TX-STATLAB
28.8.2024 13:06:34 CEST | Business Wire | Press release
StatLab Medical Products (“StatLab”), a leading global developer and manufacturer of medical diagnostic supplies and equipment, today announced that it has reached an agreement to acquire Diapath S.p.A. (“Diapath”), a prominent Italian manufacturer of histology and cytology products and equipment. The integration of Diapath, with its highly innovative equipment offerings, manufacturing capabilities, and established customer base across Europe, Asia-Pacific, Middle East and Africa, and Latin America, positions StatLab to expand its market access, unlocking significant potential for growth and enhancing its global leadership.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240828096902/en/
Diapath’s equipment portfolio, which includes tissue processors, stainers, embedding centers, and microtomes, is underpinned by its innovative development process and cutting-edge Italian design and quality, resulting in a differentiated product set that resonates with customers. (Photo: Business Wire)
The transaction is expected to close during the third quarter of 2024, subject to regulatory approvals. Upon closing, Diapath founder Vladimiro Bergamini will transition to a senior advisor role at StatLab, and Chief Operating Officer Alberto Battistel will join StatLab’s executive leadership team and help steer the Diapath business unit as its Managing Director.
“This combination is a pivotal milestone in our strategy to manufacture the full array of products supporting the entire anatomic pathology workflow,” said Sung-Dae Hong, CEO of StatLab. “Our partnership with Diapath will provide an opportunity to expand their equipment brand throughout global markets, including the U.S. The combination will also enhance StatLab’s European market access for slides, cassettes, and printers, driving our product innovation and manufacturing excellence to the next level. I’m excited to welcome Alberto and the talented Diapath team to StatLab and continue to build upon the legacy Vladimiro and his family have developed over the past three decades.”
Headquartered in Martinengo, near Bergamo, Italy, Diapath was founded in 1997 by Vladimiro Bergamini. Over the past 27 years, focused investments have enabled the business to expand beyond consumables manufacturing and into the design, development, and production of a variety of core histology instruments.
Diapath’s equipment portfolio, which includes tissue processors, stainers, embedding centers, and microtomes, is underpinned by its innovative development process and cutting-edge Italian design and quality, resulting in a differentiated product set that resonates with customers. The Diapath Donatello automatic tissue processor won a prestigious A’Design Award for Scientific Instruments, and the T-Filler Automatic Formalin dispenser protects technicians from chemical exposure while ensuring specimens receive the correct ratio of formalin. In addition to their strong Italian presence, Diapath’s subsidiaries support focused growth of Diapath products to laboratories in Germany and France.
“The decision to join StatLab is driven by our shared commitment to growth and innovation to meet customer needs,” said Vladimiro Bergamini, CEO & President of Diapath. “Our combined company will be uniquely positioned to further expand Diapath’s brand and business, together transforming the anatomic pathology market through innovative development and manufacturing. I’m looking forward to the work my team will do with Dae and StatLab to leverage our combined global manufacturing capabilities to capture new business opportunities.”
About StatLab Medical Products
StatLab Medical Products has been dedicated to helping anatomic pathology laboratories provide the best possible patient care since 1976. We offer an extensive portfolio of self-manufactured consumables and labeling and tracking equipment from eight manufacturing sites in the United States, United Kingdom, and Germany. Our global operational footprint powered by over 600 mission-driven colleagues delivers a dependable and resilient supply chain of high-quality products and solutions, and a customer-centric approach inspires us to deliver reliability, innovation, and quality in every interaction. Learn more at StatLab.com.
About Diapath
Diapath is a leading Italian company specializing in the design, development, and manufacturing of advanced histology and cytology instruments and consumables. With nearly three decades of experience, Diapath is committed to innovation and excellence, offering cutting-edge solutions that redefine laboratory processes to ensure increasingly reliable diagnostics for better cancer care. Our products, distinguished by their Italian design and quality, range from processors and stainers to embedding centers and more, supporting the entire anatomic pathology workflow. Dedicated to enhancing histological research and diagnostics, Diapath continues to set industry standards with a focus on quality and innovation. Learn more at Diapath.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240828096902/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kinaxis Announces Departure of Chief Financial Officer4.3.2026 23:00:00 CET | Press release
Leadership change comes as strong financial performance and AI-driven market momentum underpins long-term strategic growth Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that Blaine Fitzgerald, Chief Financial Officer (CFO), has advisedof his intention to step down from his role to pursue a new career opportunity with a private company outside the supply chain software space. A search will begin for a new CFO immediately. Fitzgerald remains with the company as CFO through May 8, following the company’s first quarter 2026 earnings call, to support a smooth transition. “We are grateful for Blaine’s leadership and contributions over the past six years. He has played a key role in strengthening our financial foundation, building out the financial leadership team, and advancing our AI strategy. Thanks to the depth and capability of our Senior Leadership Team, we remain well-positioned for continued success as we begin the search for our next finance
IFF Declares Dividend for First Quarter 20264.3.2026 22:15:00 CET | Press release
IFF (NYSE: IFF) announced that its Board of Directors has declared a regular quarterly cash dividend of $0.40 per share of its common stock, payable on April 10, 2026 to shareholders of record as of March 20, 2026. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience.Learn more at iff.com, LinkedIn, Instagram and Facebook. © 2026 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved. View source version on businesswire.com: https://www.businesswire.com/news/home/20260304579613/en/
Armis Named a Leader for Second Consecutive Year in 2026 Gartner® Magic Quadrant™ for CPS Protection Platforms4.3.2026 16:12:00 CET | Press release
Armis CentrixTM leveraged by global organizations to manage cyber risk across their entire attack surface Armis, the cyber exposure management & security company, today announced that it has been named a Leader in the 2026 Gartner Magic Quadrant for CPS Protection Platforms for the second consecutive year. “In an era of agentic AI, the security of our cyber-physical systems has become a strategic imperative for enterprises and governments globally; it is a pivotal pillar of global stability,” said Yevgeny Dibrov, CEO and Co-Founder of Armis. “We believe this back-to-back recognition from Gartner reflects our continued commitment to helping organizations secure the complex, critical world of CPS and reinforces the strength of our unified, proactive platform approach. Our innovation pipeline, which is aligned with our customers' needs, will continue to prioritize protecting critical environments to keep society safe and secure.” Armis was named a Leader in this report among the 13 vendor
Svante Acquires Carbon Dioxide Removal Project Developer, Carbon Alpha Corp.4.3.2026 16:00:00 CET | Press release
Svante acquires Carbon Alpha to accelerate commercial-scale carbon removal & expand its CCS/BECCS project development business in Western Canada. Acquisition adds the North Star BECCS Project, developed in partnership with the Meadow Lake Tribal Council, advancing the market for durable and verifiable CDR credits. The transaction strengthens Svante’s fully integrated carbon management platform, adding CO₂ storage expertise, a regional pipeline & a major geological storage hub. Svante Technologies Inc. (Svante), a leader in carbon management, and Calgary-based Carbon Alpha Corporation (Carbon Alpha) today announced that Svante has acquired Carbon Alpha and its related subsidiaries, including Carbon Alpha Development Corp. and its ownership interests in North Star Carbon Solutions Corp. and North Star Carbon Solutions Limited Partnership, a project developer for carbon capture and storage (CCS) in Western Canada. With this transaction, Carbon Alpha’s flagship North Star Bioenergy Carbon
Binarly Announces Leadership Transition as Enterprise Demand Accelerates for Supply-Chain Security4.3.2026 16:00:00 CET | Press release
Binarly, the industry leader in software and firmware supply‑chain security, today announced a leadership transition as the company enters its next phase of growth. Founder and current CEO Alex Matrosov has joined the company’s Board, and Gwenyth Castro has joined as Chief Executive Officer to scale global go-to-market and enterprise growth. Binarly developed its Transparency Platform on a unique, patented technology core designed to help the world’s largest enterprises identify and reduce third-party software risk across complex environments. The platform is trusted by organizations including Meta and Dell, among others. “We built Binarly to solve a problem the industry kept ignoring: you can’t secure what you can’t see,” said Alex Matrosov, Founder of Binarly. “Over the last five years, this team turned deep program analysis and vulnerability research into a platform trusted by some of the world’s most demanding enterprises. Now, as AI accelerates how software is built and shipped, t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom